Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR cardiovascular effects in acromegaly
2010-021008-77Phase 2Terminated
- Sponsor
- University of Gothenburg
- Start
- May 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in acromegaly, sponsored by University of Gothenburg. Primary endpoint: Left ventricular mass at 6 months. Started May 2011; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2010-021008-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021008-77.